中国の臭化チオトロピウム市場2010-2019

◆英語タイトル:Investigation Report on China Tiotropium Bromide Market, 2010-2019
◆商品コード:CRIR50608
◆発行会社(調査会社):China Research and Intelligence
◆発行日:2015年6月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:中国
◆産業分野:材料・製薬
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Enterprisewide(全社内共有可)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Description
In recent years, various allergic diseases demonstrate an increasing trend under the influence of global environmental changes, leading to the occurrence of seasonal cough and asthma in winter and spring. Affected by tobacco, dust and pollutants, the incidence of chronic obstructive pulmonary disease (COPD) is still on the rise. COPD is a chronic pulmonary disease characterized by incompletely reversible airflow obstruction. The major clinical manifestations are recurrent cough, expectoration, dyspnea. COPD often demonstrate a progressive characteristic, including large parts of chronic bronchitis and emphysema.
According to a survey, the incidence of COPD among people aged above 40 is 8.2% on average and higher in men (12.4%) than in women (5.1%). The number of COPD cases in China has exceeded 40 million and 65 million people are expected to die of COPD during the period of 2003-2033.
For many years, the COPD market and anti-asthmatic agents market have been dominated by four big companies – GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Merck. They take up over 80% of respiratory agents market around the world while Novartis, Roche and Teva only occupy about 10%.
Tiotropium bromide, a long-acting anticholinergic drug for inhalation, was developed by Boehringer Ingelheim. It is the first inhaler that can offer significant and lasting lung function improvement after one dosage per day. Tiotropium bromide can exert positive influence on COPD’s clinical course so as to help improve the state of patient’s life. Therefore it is widely welcomed by patients and has become the drug with the largest prescriptions in the world for the treatment of COPD. The sales value of tiotropium bromide in global market in 2013 reached nearly USD 5 billion.
According to CRI’s survey, tiotropium bromide develops fast after entering China with annual sales rising from less than CNY 1 million in 2006 to CNY 140 million in 2014 and CAGR reaching up to 90% during the period of 2006-2014. Currently, Tiotropium bromide in the Chinese market comes from the following three companies: Boehringer Ingelheim (Germany), Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Zhejiang Xianju Pharmaceutical Co., Ltd, among which Boehringer Ingelheim (Germany) has the largest market share of over 80% with sales value reaching up to CNY 114 million in 2014.
It is expected that in the next few years, tiotropium bromide market in China will keep expanding fast.

Readers can get at least the following information through this report:
-market share of manufacturers of tiotropium bromide in Chinese hospitals
-price of tiotropium bromide in Chinese hospitals
-major manufacturers of tiotropium bromide in Chinese market
-share of different dosage forms of tiotropium bromide in Chinese hospitals
-market outlook of tiotropium bromide in China

The author suggests the following groups of people purchase this report:
-manufacturers of COPD drugs
-investors interested in China COPD drug market

【レポートの目次】

Table of Contents

1 Related Concepts of Tiotropium Bromide
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Tiotropium Bromide in China
2.1 Patent and Approval Status of Tiotropium Bromide in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Tiotropium Bromide in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Tiotropium Bromide in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Tiotropium Bromide in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Tiotropium Bromide in Chinese Hospitals in 2014
6.1 Boehringer Ingelheim (Germany) (Trade Name: Spiriva)
6.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Sule)
6.3 Zhejiang Xianju Pharmaceutical Co., Ltd (Trade Name: Biduoyi)

7 Major Manufacturers of Tiotropium Bromide in Chinese Market, 2010-2014
7.1 Boehringer Ingelheim (Germany)
7.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd
7.3 Zhejiang Xianju Pharmaceutical Co., Ltd

8 Market Outlook of Tiotropium Bromide in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Selected Charts
Chart Patent Status of Tiotropium Bromide in China
Chart Approval Information of Tiotropium Bromide in China
Chart Sales Status of Tiotropium Bromide in Chinese Market, 2010-2014
Chart Sales Value of Tiotropium Bromide in China, 2010-2014
Chart Sales Value of Tiotropium Bromide in Some Regions in China, 2010-2014
Chart Sales Volume of Tiotropium Bromide in China, 2010-2014
Chart Market Share of Top3 Manufacturers of Tiotropium Bromide for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Tiotropium Bromide Made by Boehringer Ingelheim (Germany) in China, 2010-2014
Chart Sales Value and Market Share of Tiotropium Bromide Made by Chia Tai Tianqing in China, 2010-2014
Chart Sales Value and Market Share of Tiotropium Bromide Made by Xianju Pharmaceutical in China, 2010-2014
Chart Price of Tiotropium Bromide Made by Boehringer Ingelheim (Germany) in Some Chinese Cities in 2014
Chart Price of Tiotropium Bromide Made by Chia Tai Tianqing Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
Chart Price of Tiotropium Bromide Made by Zhejiang Xianju Pharmaceutical Co., Ltd in Some Chinese Cities in 2014



【掲載企業】

Boehringer Ingelheim (Germany); Chia Tai Tianqing Pharmaceutical Group Co., Ltd; Zhejiang Xianju Pharmaceutical Co., Ltd

【レポートのキーワード】

臭化チオトロピウム

★調査レポート[中国の臭化チオトロピウム市場2010-2019] (コード:CRIR50608)販売に関する免責事項を必ずご確認ください。
★調査レポート[中国の臭化チオトロピウム市場2010-2019]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆